TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8764186

Group type: EXPERIMENTAL
Intervention: Overfed and exercised (OF-EX)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Exercised (EX)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Overfed (OF)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control
Number of subjects: 21
Study: 2063158

Group type: EXPERIMENTAL
Intervention: Penicillin-G 5 million IU
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefuroxime 1.5 g
Number of subjects: 0
Study: 6862724

Group type: EXPERIMENTAL
Intervention: Thioridazine (1.0 mg/kg body wt.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thioridazine (1.5 mg/kg body wt.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thioridazine (1.0 and 1.5 mg/kg body wt.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31855102

Group type: COMPARATOR
Intervention: Endometriosis Health Profile-30 (EHP-30) intervention administered at day 1, month 3 (M3), and month 6 (M6).
Number of subjects: 1686

Group type: COMPARATOR
Intervention: EHP-30 thresholds of meaningful change.
Number of subjects: 1686

Group type: COMPARATOR
Intervention: Psychometric approaches (triangulation) used to suggest responder thresholds for EHP-30 domains.
Number of subjects: 1686
Study: 31402449

Group type: EXPERIMENTAL
Intervention: Transmuscular quadratus lumborum block
Number of subjects: 82

Group type: COMPARATOR
Intervention: Pre-peritoneal catheter block
Number of subjects: 82
Study: 27796574

Group type: EXPERIMENTAL
Intervention: Screw-retained crowns (n=53)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Cemented crowns (n=61)
Number of subjects: 58
Study: 25501016

Group type: EXPERIMENTAL
Intervention: Gd-DTPA (single bolus)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gd-DTPA (dual bolus)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gd-DTPA (nonlinear correction)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gd-BOPTA (dual bolus)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gd-BOPTA (single bolus)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gd-BOPTA (nonlinear correction)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Gd-BOPTA
Number of subjects: 10
Study: 24220352

Group type: EXPERIMENTAL
Intervention: Acyclovir added to syndromic management
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Recurrent HSV-2
Number of subjects: 422

Group type: COMPARATOR
Intervention: No specific control group mentioned
Number of subjects: 422
Study: 20726843

Group type: EXPERIMENTAL
Intervention: D-dimer levels
Number of subjects: 382
Study: 20026818

Group type: EXPERIMENTAL
Intervention: Current intensity-modulated radiation therapy (IMRT) protocol using the Pinnacle(3) planning system
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional lateral opposing-field radiation or initial IMRT protocol using the Best nomos PEACOCK planning system
Number of subjects: 104
Study: 16950654

Group type: EXPERIMENTAL
Intervention: Email-delivered, pedometer-based intervention with TTM strategies
Number of subjects: 74

Group type: COMPARATOR
Intervention: Email-delivered, pedometer-based intervention without TTM strategies
Number of subjects: 74
Study: 15083241

Group type: EXPERIMENTAL
Intervention: Demand feeding
Number of subjects: 11

Group type: COMPARATOR
Intervention: Scheduled feeding
Number of subjects: 11
Study: 12023504

Group type: EXPERIMENTAL
Intervention: Stress reduction interventions (not specified if alone or in combination with pharmacotherapies targeting the HPA axis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drugs affecting the synthesis and/or secretion of corticosterone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticosterone increase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone (CRH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stressors or cocaine-associated cues during abstinence
Number of subjects: 0
Study: 10463960

Group type: EXPERIMENTAL
Intervention: Budesonide 400 mg twice daily for two weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 7751683

Group type: EXPERIMENTAL
Intervention: OPV containing twice the standard potency of Sabin type 1 virus
Number of subjects: 1409

Group type: COMPARATOR
Intervention: Standard formulations of OPV
Number of subjects: 1409
Study: 2261610

Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fluoride
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 555487

Group type: EXPERIMENTAL
Intervention: Special behavior therapy group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular behavior therapy group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychotherapy group
Number of subjects: 0
Study: 6362465

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low dose of alcohol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High dose of alcohol
Number of subjects: 24
Study: 29702033

Group type: EXPERIMENTAL
Intervention: Video biography
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Video with b-roll biography
Number of subjects: 523

Group type: COMPARATOR
Intervention: Text-only biography
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Video biography (a-roll only)
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Video including added b-roll
Number of subjects: 523
Study: 27533472

Group type: EXPERIMENTAL
Intervention: Oral rehydration solution (500 mL) before abdominal and pelvic CT; n = 2244 patients.
Number of subjects: 5959

Group type: COMPARATOR
Intervention: Control group (no rehydration); n = 2244 patients (adjusted control group).
Number of subjects: 5959

Group type: EXPERIMENTAL
Intervention: Subclinically dehydrated group; n = 997 patients.
Number of subjects: 5959

Group type: EXPERIMENTAL
Intervention: Hydrated group; n = 4962 patients.
Number of subjects: 5959
Study: 25631723

Group type: EXPERIMENTAL
Intervention: NaOCl 2.5%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Biopure MTAD™
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.9% Saline (Control)
Number of subjects: 40
Study: 23195668

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 20919574

Group type: EXPERIMENTAL
Intervention: Reamberin (400 ml/day for 10 days)
Number of subjects: 427
Study: 18842392

Group type: EXPERIMENTAL
Intervention: 40 mg of isoflavone
Number of subjects: 47

Group type: COMPARATOR
Intervention: 40 mg of casein placebo
Number of subjects: 47
Study: 16103382

Group type: EXPERIMENTAL
Intervention: P6 acupressure
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Placebo acupressure
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 12050246

Group type: EXPERIMENTAL
Intervention: GH treatment (2 IU/m(2).d)
Number of subjects: 25
Study: 10332942

Group type: EXPERIMENTAL
Intervention: 10-s breathhold while supine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10-s breathhold while standing
Number of subjects: 12

Group type: COMPARATOR
Intervention: Comparison of supine vs standing during breathhold
Number of subjects: 12
Study: 7483152

Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0
Study: 2031520

Group type: EXPERIMENTAL
Intervention: Ofloxacin, 400 mg twice daily for 10 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Cefoxitin, 2 gm intramuscular plus probenecid, 1 gm, followed by doxycycline, 100 mg twice daily for 10 days
Number of subjects: 38
Study: 6759242

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Multiple subcutaneous injections (MSI)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both CSII and MSI
Number of subjects: 16
Study: 31552584

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 20 mg per day for 14 days
Number of subjects: 53

Group type: COMPARATOR
Intervention: Prednisolone once daily for 14 days
Number of subjects: 53
Study: 30892477

Group type: EXPERIMENTAL
Intervention: Hyperinflation with mechanical ventilator + vibrocompression
Number of subjects: 93

Group type: COMPARATOR
Intervention: Tracheal aspiration alone
Number of subjects: 93
Study: 28068938

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with methylcobalamin (Met + Acu)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Methylcobalamin alone
Number of subjects: 104
Study: 27255280

Group type: EXPERIMENTAL
Intervention: Mindfulness audios
Number of subjects: 90

Group type: COMPARATOR
Intervention: Audios of readings from a non-fiction book
Number of subjects: 90
Study: 25127178

Group type: EXPERIMENTAL
Intervention: Trauma-focused Exposure Therapy (EXP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Health & Lifestyles (HLS)
Number of subjects: 120
Study: 22559092

Group type: EXPERIMENTAL
Intervention: MSB‐Nutrition program
Number of subjects: 320

Group type: COMPARATOR
Intervention: On‐campus weight management course
Number of subjects: 320

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 320
Study: 19243606

Group type: EXPERIMENTAL
Intervention: KAb201 via intra-arterial route at 50 mCi
Number of subjects: 25

Group type: COMPARATOR
Intervention: KAb201 via intravenous route at 50 mCi
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Overall response rate
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Median overall survival
Number of subjects: 25
Study: 17113309

Group type: EXPERIMENTAL
Intervention: Intentional movements to produce an effect (tone) with a success ratio of 2:1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Removal of intentional attribution of the effect
Number of subjects: 0
Study: 15196110

Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg
Number of subjects: 495

Group type: COMPARATOR
Intervention: No prophylactic antiemetic
Number of subjects: 495
Study: 11485528

Group type: EXPERIMENTAL
Intervention: Ultrasonic dissector
Number of subjects: 132
Study: 9669465

Group type: EXPERIMENTAL
Intervention: Stabilization appliance
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control appliance
Number of subjects: 60
Study: 7838618

Group type: EXPERIMENTAL
Intervention: He‐O2 mixture (20.9% O2/79.1% He)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Air
Number of subjects: 11
Study: 3362274

Group type: EXPERIMENTAL
Intervention: sulindac 200 mg p.o. b.i.d.
Number of subjects: 74

Group type: COMPARATOR
Intervention: indomethacin 25 mg p.o. t.i.d. and 100 mg p.r.
Number of subjects: 74
Study: 31149841

Group type: EXPERIMENTAL
Intervention: Cervicothoracic transcutaneous electrical nerve stimulation (CTENS) - 30 min twice daily, 80-Hz frequency, 150-μs pulse duration for 14 days
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cervicothoracic transcutaneous electrical nerve stimulation (CTENS)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 17
Study: 28786995

Group type: EXPERIMENTAL
Intervention: Facilitated case conferencing (FCC)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 286
Study: 25795959

Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 22861816

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) with balance training for two weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Balance training alone for two weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 21
Study: 21859765

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 19124524

Group type: EXPERIMENTAL
Intervention: Abatacept plus methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 0
Study: 16415316

Group type: EXPERIMENTAL
Intervention: BIS 40-50, effect site remifentanil concentration 1 ng ml(‐1)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: BIS 40-50, remifentanil 2 ng ml(‐1)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: BIS 40-50, remifentanil 4 ng ml(‐1)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: BIS 25-35, remifentanil 2 ng ml(‐1)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: BIS 55-65, remifentanil 2 ng ml(‐1)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: PPG variation in responders
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: PPG variation
Number of subjects: 95
Study: 15553107

Group type: EXPERIMENTAL
Intervention: 30 mg intravenous orphenadrine citrate
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 11568514

Group type: COMPARATOR
Intervention: 20 mg/1.73 m2
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 40 mg/1.73 m2
Number of subjects: 9
Study: 9333107

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg/day for 28 days
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg/day for 28 days
Number of subjects: 44

Group type: COMPARATOR
Intervention: Coadministration of pravastatin or lovastatin with cyclosporine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pravastatin and lovastatin
Number of subjects: 44
Study: 8408451

Group type: EXPERIMENTAL
Intervention: Dexamethasone (1.5 mg) pretreatment
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Haloperidol treatment (0.05 mg/kg, i.v.)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo pretreatment
Number of subjects: 2
Study: 3936774

Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 43
Study: 31651335

Group type: EXPERIMENTAL
Intervention: Rapael Smart Board™ (SB) with 30 min of intervention and 30 min of standard occupational therapy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Rapael Smart Board™ (SB)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (CON) with 60 min of conventional occupational therapy
Number of subjects: 26
Study: 29084736

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/d target dose)
Number of subjects: 3876

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3876
Study: 24986061

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with CoQ (Med + CoQ diet)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saturated fat diet
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mediterranean diet
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-fat, high-carbohydrate diet enriched in n-3 polyunsaturated fat
Number of subjects: 10
Study: 23857856

Group type: EXPERIMENTAL
Intervention: Fixed-ratio (1:1:1) transfusion protocol
Number of subjects: 78

Group type: COMPARATOR
Intervention: Laboratory-results-guided transfusion protocol (control)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 78
Study: 21338804

Group type: EXPERIMENTAL
Intervention: High energy diet (OVR) - 1.62 Mcal of NE<sub>L</sub>/kg; 15% crude protein, ad libitum intake
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control diet (CON) - 1.21 Mcal of NE<sub>L</sub>/kg; 14.2% crude protein, 100% NRC requirements
Number of subjects: 47

Group type: COMPARATOR
Intervention: Restricted intake diet (RES) - 1.62 Mcal of NE<sub>L</sub>/kg; 15% crude protein, 80% of energy requirements
Number of subjects: 47
Study: 19379491

Group type: EXPERIMENTAL
Intervention: Real-time perfusion contrast echocardiography using angiomode (AM)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Real-time perfusion contrast echocardiography using high-resolution grayscale (HR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: SPECT
Number of subjects: 50
Study: 17678780

Group type: EXPERIMENTAL
Intervention: Cerebral near-infrared spectroscopy (NIRS)
Number of subjects: 35
Study: 15006949

Group type: EXPERIMENTAL
Intervention: Eucapnic voluntary hyperventilation (EVH) for 6 min inhaling dry air containing 5% carbon dioxide at a target ventilation of 30 times baseline FEV(1)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Field exercise (cross-country skiing, ice skating, or running for 6 to 8 min)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Eucapnic voluntary hyperventilation (EVH)
Number of subjects: 38
Study: 11793265

Group type: EXPERIMENTAL
Intervention: Internal Nasal Dilator (Nasanita)
Number of subjects: 0
Study: 7756941

Group type: EXPERIMENTAL
Intervention: Biokit ELISA
Number of subjects: 8

Group type: COMPARATOR
Intervention: Murex assay
Number of subjects: 8
Study: 2837033

Group type: EXPERIMENTAL
Intervention: Cytobrush
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cotton swab
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cytobrush and Cotton swab
Number of subjects: 200
Study: 31668138

Group type: EXPERIMENTAL
Intervention: Behaviour-change intervention for physical activity (PA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 31276810

Group type: EXPERIMENTAL
Intervention: Inpatient specialist palliative care consultations and outpatient phone follow-up by a palliative care nurse
Number of subjects: 63

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 63
Study: 29102440

Group type: EXPERIMENTAL
Intervention: Radioguided Occult Lesion Localisation using Iodine‐125 Seed (ROLLIS)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Conventional Hookwire Localisation (HWL)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Multiple localisation devices
Number of subjects: 218
Study: 25794531

Group type: EXPERIMENTAL
Intervention: Toothpaste with 1100 ppm F supplemented with 3% TMP
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Toothpaste with 1100 ppm F
Number of subjects: 84

Group type: COMPARATOR
Intervention: Toothpaste without F and TMP (placebo)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Toothpaste with 1100 ppm F supplemented with 1% TMP
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Toothpaste with 1100 ppm F supplemented with 4.5% TMP
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Toothpaste with 1100 ppm F supplemented with 6% TMP
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Toothpaste with 1100 ppm F supplemented with 9% TMP
Number of subjects: 84
Study: 23736111

Group type: EXPERIMENTAL
Intervention: Resistance exercise training (PHRT)
Number of subjects: 43
Study: 21477503

Group type: EXPERIMENTAL
Intervention: Personal barriers to walking and physical activity
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Built-environment barriers to walking and physical activity
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Facilitators to walking
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Health-related quality of life
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Mental health quality of life
Number of subjects: 75
Study: 18639296

Group type: EXPERIMENTAL
Intervention: 10 mg vardenafil
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 17040006

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (4.5, 6.0, or 9.0 g per day)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 14690184

Group type: EXPERIMENTAL
Intervention: On-site QCA analysis
Number of subjects: 116

Group type: COMPARATOR
Intervention: Core laboratory QCA analysis
Number of subjects: 116
Study: 10627097

Group type: EXPERIMENTAL
Intervention: Self-reported drinking at treatment admission
Number of subjects: 1726

Group type: EXPERIMENTAL
Intervention: Self-reported drinking at 15-month follow-up
Number of subjects: 1726

Group type: EXPERIMENTAL
Intervention: Blood chemistry values (liver function tests) at treatment admission
Number of subjects: 1726

Group type: EXPERIMENTAL
Intervention: Blood chemistry values (liver function tests) at 15-month follow-up
Number of subjects: 1726

Group type: EXPERIMENTAL
Intervention: Discrepancies in self-report vs. biochemical measures
Number of subjects: 1726
Study: 9002097

Group type: EXPERIMENTAL
Intervention: Personalized recall letters mailed to parents (n=153)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Control group (n=136)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Projected recall letter policy for regional population
Number of subjects: 289
Study: 7957001

Group type: EXPERIMENTAL
Intervention: High fibre reducing diet for 6 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (non-dieting)
Number of subjects: 16
Study: 3592329

Group type: EXPERIMENTAL
Intervention: Intramuscular chlorpromazine (CPZ) 1 mg/kg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intramuscular chlorpromazine (CPZ)
Number of subjects: 36
Study: 28980220

Group type: EXPERIMENTAL
Intervention: Machine Training (MT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Free Weight Training (FWT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 45
Study: 26954409

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study: 25460343

Group type: EXPERIMENTAL
Intervention: Wii-Fit group
Number of subjects: 128

Group type: COMPARATOR
Intervention: Usual rehabilitative care group
Number of subjects: 128
Study: 23183252

Group type: EXPERIMENTAL
Intervention: Behavioral family based intervention
Number of subjects: 96

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 96
Study: 21218270

Group type: EXPERIMENTAL
Intervention: Workplace ergonomic improvements (Intervention group, N=89)
Number of subjects: 177
Study: 18344738

Group type: EXPERIMENTAL
Intervention: PRX-00023 (80 mg/d)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study: 16797903

Group type: EXPERIMENTAL
Intervention: Resistance training plus vitamin D 400 IU plus 800 mg of calcium per day
Number of subjects: 96

Group type: COMPARATOR
Intervention: Resistance training plus calcium alone
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Non-trained subjects supplemented with vitamin D
Number of subjects: 96

Group type: COMPARATOR
Intervention: Non-trained subjects without vitamin D supplementation
Number of subjects: 96
Study: 14557356

Group type: EXPERIMENTAL
Intervention: Bone marrow-derived progenitor cells (BMCs) or circulating progenitor cells (CPCs) infused into the infarct artery 4.7±1.7 days after AMI
Number of subjects: 28
Study: 11094584

Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg (T1)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Tramadol 200 mg (T2)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Saline (S)
Number of subjects: 29